Fresenius Group Overview

Fresenius Kabi

Industrial production of infusion solutions at Fresenius Kabi's plant in Friedberg.

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.

Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.

With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

Fresenius Kabi employs over 36,000 people worldwide. In 2018 the company reported sales of more than €6 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.

 

 

Key figures (IFRS)
€ in millions

2018

2017

Change

Sales

6,544

6,358

+ 3 %

EBIT

1,139

1,177

- 3 %

Net income

742

702

+ 6 %

Operating cash flow

1,040

1,010

+ 3 %

Capital expenditure/acquisitions

615

585

+ 5 %

R & D expenses 534

427

+ 25 %

Employees (December 31)

37,843

36,380

+ 4 %

  • Some figures adjusted for special items
  • Net income = Net income attributable to shareholders of Fresenius Kabi